Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Michael Cipriano

Washington, DC
Michael Cipriano is a writer based in Washington, D.C. who covers FDA regulatory policy. He has primarily written about advisory committees, FDA public meetings and drug regulation. He is also part of the Pink Sheet’s efforts to expand coverage into Latin America. Previously, Michael has covered generic drug and biosimilar regulation, as well as issues impacting clinical trials.
Advertisement
Set Alert for Articles By Michael Cipriano

Latest From Michael Cipriano

Keeping Track: FDA's Review Actions Carry On During Shutdown

The latest drug development news and highlights from our US FDA Performance Tracker.
US FDA Performance Tracker Drug Review

Evenity Likely Headed For Approval With Amgen's Proposed Indication, But Postmarketing Requirements Remain Unclear

US FDA advisory committee splits on whether Amgen's osteoporosis drug romosozumab needs observational study or randomized controlled trial to assess cardiovascular risks. 
Advisory Committees Orthopedics

Shutdown Bite Tightens At US FDA, But Gene Therapy To Get 50 More Reviewers

FDA continues to emphasize the routine and the positive, even though strains on staff and sponsors increase as shutdown grinds on. CBER's new clinical reviewers would oversee the clinical investigation, development and review of cell and gene therapies, although a timeline on the hiring is unclear.

Biologics Regenerative Medicine

Amgen's Evenity Faces CV Safety Gauntlet At US FDA Advisory Cmte.

Narrower indication and a boxed warning for Amgen's osteoporosis drug romosozumab might be sufficient to permit approval.  
Advisory Committees Drug Safety

Keeping Track: A Week Of Calm As Shutdown Drags On

The latest drug development news and highlights from our US FDA Performance Tracker.
Drug Review Regulation

Democrats’ Drug Pricing Bills Echo Trump Ideas But Broad Republican Support Unlikely

Upcoming House Oversight Committee hearing on drug pricing offers a chance for fireworks, but broader prospects for new Democratic pricing legislation seem limited.
Legislation Medicare
See All
Advertisement
UsernamePublicRestriction

Register